Attenuated response to SARS-CoV-2 vaccine in patients with asymptomatic precursor stages of multiple myeloma and Waldenstrom macroglobulinemia

Cancer Cell. 2022 Jan 10;40(1):6-8. doi: 10.1016/j.ccell.2021.12.003. Epub 2021 Dec 9.

Authors

Yoshinobu Konishi¹, Romanos Sklavenitis-Pistofidis¹, Hong Yue², Federico Ferrari³, Robert A Redd³, Elizabeth D Lightbody¹, Massimiliano Russo³, Jacqueline Perry⁴, Erica Horowitz⁴, Anna V Justis⁴, Nader A Shayegh⁴, Alexandra Savell⁴, Julia Prescott⁴, Shohreh Varmeh⁴, Radosław P Nowak², Mark Hamilton⁵, Daniel Auclair⁵, Catherine R Marinac⁴, Lorenzo Trippa³, Eric S Fischer², Irene M Ghobrial⁶

Affiliations

¹ Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; Broad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA, USA.
² Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, USA; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA, USA.
³ Department of Data Science, Dana-Farber Cancer Institute, Boston, MA, USA.
⁴ Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
⁵ Multiple Myeloma Research Foundation (MMRF), Norwalk, CT, USA.
⁶ Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; Broad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA, USA. Electronic address: irene_ghobrial@dfci.harvard.edu.

No abstract available

Publication types

Letter

MeSH terms

Ad26COVS1 / immunology*
Antibodies, Viral / biosynthesis*
Asymptomatic Diseases
BNT162 Vaccine / immunology*
COVID-19 / epidemiology
COVID-19 / prevention & control*
COVID-19 Vaccines
Female
Humans
Immunocompromised Host
Immunogenicity, Vaccine
Immunoglobulin G / biosynthesis*
Immunologic Tests
Male
Models, Immunological
Multiple Myeloma / immunology*
Prospective Studies
Risk
SARS-CoV-2 / immunology*
Waldenstrom Macroglobulinemia / immunology*

Substances

Ad26COVS1
Antibodies, Viral
COVID-19 Vaccines
Immunoglobulin G
BNT162 Vaccine

Supplementary concepts

COVID-19 breakthrough infections

Grants and funding

K22 CA251648/CA/NCI NIH HHS/United States